ETView Medical, Ltd., and NeuroMed Ltd. (NeuroMed), executed distribution agreement
The agreement enables NeuroMed to market ETView's VivaSight™ platform in Russia.
Feb. 7, 2012, Tel Aviv, Israel‐‐ETView Medical Ltd. (TASE: ETVW) announced today that it has entered into a distribution agreement with NeuroMed Ltd. (NeuroMed). The agreement
enables NeuroMed to market ETView's VivaSight™ platform (previously known as TVT™), combining an airway ventilation tube with integrated continuous high resolution airway imaging for patient airway control and lung isolation capability in Russia for a period of 2 years.
William Edelman, CEO of ETView Medical, commented, “We are excited to add NeuroMed to our expanding distributor network.” Mr. Edelman continued, “VivaSight™ is currently being distributed across Europe and the United States. VivaSight™ provides best‐in‐class airway management solutions for sophisticated thoracic surgical procedures requiring lung isolation.”
On February 2, 2012, ETView announced a distribution agreement with State of the Art (SOTA) Medical Products, Inc., a specialty surgical products sales and distribution company, based in Cedar Grove, New Jersey.
On December 12, 2011, ETView announced that the company has successfully completed filing of a Pre‐Marketing Notification Application (510(k)) with the US Food and Drug Administration (FDA) for the VIVASIGHT™‐DL1 Airway Management System. VIVASIGHT™‐DL is a proprietary, single‐use disposable medical device, consisting of a dual‐lumen airway ventilation tube with an integrated, continuous, high‐resolution video airway imaging system permitting airway control and lung isolation during certain surgical procedures. Lung isolation is employed to provide one‐lung ventilation in patients undergoing thoracic, cardiac, vascular, or esophageal surgeries.2 During lung isolation, temporary visualization of the patient airway is achieved with a fiberoptic bronchoscope while the patient is ventilated and the target lung isolated. Intraoperative surgical maneuvers often require repeated imaging and partial blocking of the airway to maintain lung isolation.3 It is estimated that over 1.9 million lung isolation procedures are conducted worldwide annually,4 accounting for over $250MM in single‐use medical disposables.5 ETView has pioneered development of the VivaSight™ platform (previously known as TVT™), combining an airway ventilation tube with integrated continuous high resolution airway imaging for patient airway control and lung isolation capability (eliminating the need for fiberoptic bronchoscope6 imaging during these procedures). Additional pre‐market regulatory filings in Europe and Asia are anticipated during 2012.
About NeuroMed Ltd.
According to information provided to the company, NeuroMed Ltd. (NeuroMed) is a surgical products sales and distribution company servicing healthcare institutions throughout Russia, based in St. Petersberg, Russia. Founded in 2006, NeuroMed concentrates medical device product sales and support in anesthesiology, intensive care, general surgery, cardiovascular surgery and spine surgery. In addition to ETView, NeuroMed represents multiple medical device divisions of Johnson and Johnson, including Cordis and Codman. Additionally, NeuroMed represents the Rusch line of anesthesia products for Teleflex Medical.
About ETView, Medical, Ltd.
ETView Medical Ltd. (TASE: ETVW) has successfully combined airway management with continuous, direct airway visualization for medical professionals. ETView's patented VivaSight™‐SL, a single‐use, disposable medical device consisting of a single‐lumen ventilation tube with an integrated continuous high resolution video imaging system, is currently sold in Europe, Israel, and the US to overcome current limitations and associated adverse surgical events during lung isolation surgeries.7 It is estimated that over 1.9 million lung isolation procedures are conducted worldwide annually,8 accounting for over $250MM in single‐use medical disposables.9 Visit www.etview.com for additional information.
The Company estimations in this press release, including those estimations regarding the Company's predicted scope of business, constitute forward‐looking statements, as such term is defined under the Israeli Securities Law (5728‐1968), and there is no certainty that such estimations shall materialize. The Company's estimations are based on business assumptions, prior experience, and professional data. Due to various factors, foreseen and unforeseen, including, but not limited to, changes in market trends, competition, global or local economic conditions, and amendments of regulation, such estimations may not materialize in whole or in part, or materialize in a substantially different manner than anticipated by the Company.
1 Patent Pending
2 Principles and Practices of Anesthesia for Thoracic Surgery. P. Singer (ed.) 2011
3 Anesthesia & Analgesia. 2009;108:1097–101
4 National Health Statistics Reports Number 29, October 26, 2010
5 Company estimates on file
6 Minerva Anestesiol. 2009;75(Suppl 1):1-4.
7 Anesthesiology. 2006;105:471-477.
8 National Health Statistics Reports Number 29, October 26, 2010
9 Company estimates on file